National Bank of Greece (ETE),(NBGA),(NBG) is a Greece global banking and financial service company with its headquarters in Athens, Greece. The bank offers financial products, and services, brokerage, insurance, asset management, shipping finance, leasing and factoring markets. It was founded by Swiss banker Jean-Gabriel Eynard and George Starvros in 1841 as a commerical bank. From its inception until the establishment of the Bank of Greece in 1928, it had the right to issue banknotes. The bank listed on the Athens Stock Exchange right after its founding in the 1880s.
Company History & Operations
National Bank of Greece was formed in 1841 in Athens, making it the oldest bank in the country. It wasn't government owned from its inception, but had the right of note issue, which it lost in 1928 when Greece established its own central bank. The bank in 1899 aquired the Privileged Bank of Epirus and Thessaly.
At the beginning of the 20th century the bank began its international expansion. In 1956 the bank aquired the Bank of Athens, which was at the time the second largest bank in Greece. The bank in 1965 aquired the Greek Tapeza Epagelmatikis Pristis (Professional Credit Bank). In 1966 bank governor Georgios Mavros founded the National Bank of Greece Cultural Foundation. Since the 1999 the bank has been listed on the New York Stock Exchange. In banking it sold all its operations in Canada to the Bank of Nova Scotia in 2005. The next year the bank sold its U.S. arm, Altantic Bank of New York, to New York Community Bancorp for $400 million (EUR 331 million) in cash. It used the proceeds from these sells to finance aquisitions in Southern Europe.
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion: - [By Anders Bylund]
And then there's cancer drug developer Pharmacyclics (NASDAQ: PCYC ) . This stock had been trading like a roller coaster when the poison pill quietly got the kibosh, and continued to trade sideways for another couple of years. Then Pharmacyclics' cancer treatments made some headway in FDA proceedings led by leukemia drug Ibrutinib, sending the stock on a rocket ride. Pharmacyclics' returns of 2,500% since the plan change make the S&P 500's 45% jump look like dead money. And Pharmacyclics may work together with some big partners, but remains a separate business to this day.
Top 10 Shipping Companies For 2014: China Ming Yang Wind Power Group Ltd (MY)
China Ming Yang Wind Power Group Limited incorporated on February 26, 2009, is a wind turbine manufacturer in China, focusing on designing, manufacturing, selling and servicing megawatt-class wind turbines. The Company�� products consist of basic models of wind turbines, each with a rated power capacity of 1.5 megawatt (MW); wind turbines with a rated power capacity of 2.0MW, and 2.5/3.0MW SCD wind turbines. Each product type may be installed with one of three rotor blade models depending on the location and wind conditions. As of December 31, 2012, the Company had entered into sales contracts with 37 end customers to deliver 3,730 units of its wind turbines.
It cooperates with aerodyn Energiesysteme to develop its 1.5 megawatt wind turbines and share intellectual property rights. It also has obtained licenses from aerodyn Asia Co., Ltd. (aerodyn Asia) to manufacture and distribute wind turbines utilizing its super-compact drive (SCD) technology, with a rated power capacity of 6.0MW.
The Company�� customers are the Chinese state-owned power producers which include Huaneng, China Datang, Huadian, China Guodian Corporation, and China Power Investment Corporation (CPIC) or their alternative energy subsidiaries, such as China Longyuan Power Group Corporation Limited (Longyuan), a subsidiary of Guodian, and China Datang Corporation Renewable Power Co., Limited (Datang Renewable), a subsidiary of China Datang. It also sells wind turbines to regional alternative energy investment companies, regional power producers and wind farm operators in the private sector. Its facilities are located in Zhongshan, Tianjin, Jilin, Rudong, Dali and Inner Mongolia in China.
The Company produces megawatt-class, grid-connected, horizontal-axis wind turbines, equipped with a double-fed constant frequency induction generator, which is a design of the generator that enables the generator to produce electric current of a constant frequency as the shaft rotates at varying speeds causing! the generator rotor to rotate at varying speed. It offers 1.5 megawatt turbines specially designed and developed for the wind and weather conditions and power grids in China. Its 1.5 megawatt wind turbines are equipped with rotor blades with a post-installation diameter of 77.1 meters, 82.6 meters or 89.0 meters.
The Company has license rights under a license agreement from aerodyn Asia to manufacture and distribute 2.5/3.0MW SCD wind turbines and 6.0MW SCD wind turbines in China. The Company is focused on developing 3.8MW wind turbine model for larger multi-megawatt wind turbines.
The Company competes with Sinovel, Goldwind, Dongfang Electric, United Power, Vestas, Gamesa Corporacion Tecnologica S.A. and GE Energy.
Advisors' Opinion: - [By Garrett Cook]
In trading on Tuesday, industrials shares were relative leaders, up on the day by about 0.26 percent. Top gainers in the sector included Perceptron (NASDAQ: PRCP), up 10.9 percent, China Ming Yang Wind Power Group (NYSE: MY), up 4.8 percent.
- [By Travis Hoium]
What: Shares of wind turbine maker China Ming Yang Wind Power Group (NYSE: MY ) jumped as much as 17% after reporting earnings.
So what: Total revenue in the first quarter was up 98% to $129.7 million, and comprehensive income was $3.8 million, or $0.03 per share. This result is a swing back to profit for the company, and it looks like demand is picking up quickly this year. �
Top 10 Shipping Companies For 2014: Steinway Musical Instruments Inc. (LVB)
Steinway Musical Instruments, Inc., through its subsidiaries, designs, manufactures, markets, and distributes musical instruments in the United States and internationally. The company operates in two segments, Pianos and Band & Orchestral Instruments. The Pianos segment offers pianos under Steinway & Sons, Boston, and Essex brands; and engages in online music retailing business. This segment sells its products to professional artists and amateur pianists, and institutions through independent dealers primarily in the United States, Germany, Austria, Switzerland, the United Kingdom, France, and Italy. It operates six retail showrooms in the United States and five retail showrooms in Europe. The Band & Orchestral Instruments segment manufactures and sells piccolos, flutes, clarinets, oboes, bassoons, trumpets, French horns, tubas, and trombones, as well as intermediate and professional level woodwind and brass instruments under Bach, Selmer, Selmer Paris, C.G. Conn, Leblanc, King, Armstrong, Holton, Yanagisawa, Vito, Emerson, Avanti, Noblet, Artley, and Benge brands; distributes saxophones and clarinets; manufactures and distributes acoustical and tuned percussion instruments, including outfit drums, marching drums, concert drums, marimbas, xylophones, vibraphones, orchestra bells, and chimes; distributes violins, violas, cellos, and basses under Glaesel, Scherl & Roth, and William Lewis & Son brands; and manufactures mouthpieces and distributes accessories, such as music stands, batons, mallets, straps, mutes, reeds, pads, chin rests, strings, bows, cases, and instrument care products. This segment sells its products to students, amateur and professional musicians, and institutions through independent musical instrument dealers and distributors primarily in the United States, Europe, Latin America, and Asia. The company, formerly known as Selmer Industries, Inc., was founded in 1993 and is based in Waltham, Massachusetts.
Advisors' Opinion: - [By Eric Volkman]
Steinway Musical Instruments (NYSE: LVB ) has ceased to be the owner of its iconic Steinway Hall in New York City. The company formally closed a deal to sell the building to a partnership headed by real estate concern JDS Development Group. Steinway received $46.3 million in the acquisition, and will recognize a taxable gain of roughly $22 million.
Top 10 Shipping Companies For 2014: Medivation Inc.(MDVN)
Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of castration-resistant prostate cancer, Alzheimer?s disease, and Huntington disease. The company?s product candidates under clinical development include MDV3100, which is in Phase 3 development for the treatment of castration-resistant prostate cancer; and dimebon, which is in Phase 3 clinical trial for the treatment of Alzheimer?s disease and Huntington disease. It has collaboration agreements with Pfizer Inc. to develop and commercialize dimebon; and Astellas Pharma Inc. to develop and commercialize MDV3100. The company was founded in 2003 and is based in San Francisco, California.
Advisors' Opinion: - [By Sean Williams]
Friday brought equally good news for Medivation (NASDAQ: MDVN ) and its advanced prostate cancer drug Xtandi, which also received a positive opinion from the EMA's advisory panel. This really shouldn't come as a surprise as Medivation's oral prostate cancer treatment won FDA approval months early in the U.S., and the 4.8 months of extended median survival it delivered compared to the placebo is remarkable for such an advanced stage disease.
Top 10 Shipping Companies For 2014: Altisource Residential Corp (RESI)
Altisource Residential Corporation is a development-stage company engaged in the acquisition and ownership of single-family rental assets. The Company�� primary sourcing strategy to acquire these assets includes purchase of sub-performing and non-performing mortgages, as well as single-family homes at or following the foreclosure sale (REO Properties (REO)).
The Company intends to pursue opportunities to acquire its single-family rental assets throughout the United States. The Company is managed by Altisource Asset Management Corporation (AAMC). On December 21, 2012, Altisource Residential Corporation�� spin-off from Altisource Portfolio Solutions S.A. (Altisource) was completed.
Advisors' Opinion: - [By Mark Holder]
Altisource Residential (NYSE: RESI ) (NYSE: RESI ) (NYSE: RESI ) purchases distressed mortgage loan portfolios with a strategy to work with borrowers to modify and refinance loans to either keep them in their homes or convert the unmodified loans into renovated rental properties.
- [By Amanda Alix]
For Wall Street types, single-family foreclosures can be bought cheaply and in bulk, then fixed up and rented. Companies like the Blackstone Group (NYSE: BX ) and Colony Financial (NYSE: CLNY ) have been very active in this market, with the former purchasing 16,000 homes just last year, and the latter ramping up its own portfolio to approximately 7,000. This new industry has also spawned fresh entrants from the REIT field, Silver Bay Realty (NYSE: SBY ) and Altisource Residential, (NYSE: RESI ) two trusts that were spun off earlier this year from parent companies Two Harbors Investment (NYSE: TWO ) and Altisource Portfolio Solutions (NASDAQ: ASPS ) , specifically to take advantage of the boom in the foreclosure-to-rental market.
Top 10 Shipping Companies For 2014: EQT Corporation(EQT)
EQT Corporation, together with its subsidiaries, operates as an integrated energy company in the United States. It operates in three segments: EQT Production, EQT Midstream, and Distribution. The EQT Production segment engages in the exploration, development, and production of natural gas, natural gas liquids, and crude oil in the Appalachian Basin. This segment?s properties are located primarily in Kentucky, West Virginia, Virginia, and Pennsylvania. As of December 31, 2010, it had 5.2 trillion cubic feet of proved reserves across 3.5 million acres. The EQT Midstream segment provides gathering, processing, transmission, and storage services for the independent third parties in the Appalachian Basin. It has approximately 10,900 miles of gathering lines and 770 miles of transmission lines. The Distribution segment distributes and sells natural gas to residential, commercial, and industrial customers in southwestern Pennsylvania, West Virginia, and eastern Kentucky. It also operates a gathering system in Pennsylvania; and purchases and delivers gas to customers. This segment serves approximately 276,500 customers consisting of 257,900 residential customers, and 18,600 commercial and industrial customers. The company was formerly known as Equitable Resources, Inc. and changed its name to EQT Corporation in February 2009. EQT Corporation was founded in 1925 and is headquartered in Pittsburgh, Pennsylvania.
Advisors' Opinion: - [By Dave and Donald Moenning]
Nevertheless, when the "necessary pullback" during bull runs does happen, certain spaces get slammed. Wednesday, it looks like Semiconductors and Oil & Gas Exploration & Production are the sub-industries taking a beating. While it's probably not the greatest strategy to pick out buys in problem areas, EQT Corp (EQT) presents itself as a great buy this morning.
- [By Matt DiLallo]
The�Marcellus is well-known for its�low cost of production, which is why many drillers have seen it fuel a recent surge in their stock prices. Marcellus-focused companies like Range Resources (NYSE: RRC ) , Cabot Oil & Gas (NYSE: COG ) , and EQT Resources (NYSE: EQT ) are among those enjoying a nice run so far this year as you can see in the following chart:
- [By Matt DiLallo]
Unfortunately for XTO Energy, there was one small and, unbeknownst to anyone, unresolved matter. You see, LINN had a contract to sell its gas through a unit of Dominion Resources (NYSE: D ) , which was gathering the gas in its system. However, LINN's gas wasn't up to the system's standards, so it began to look for another gatherer and it approached Equitrans, which is now part of EQT Midstream Partners (NYSE: EQM ) but formerly was a unit of EQT Corp. (NYSE: EQT ) -- they talked, but nothing was signed. However, an EQT employee later that year thought that it had and began crediting gas to the wrong company.
Top 10 Shipping Companies For 2014: Oiltanking Partners LP (OILT)
Oiltanking Partners, L.P. (OTLT) is engaged in the terminaling, storage and transportation of crude oil, refined petroleum products and liquefied petroleum gas. Through its wholly owned subsidiaries, Oiltanking Houston, L.P. (OTH) and Oiltanking Beaumont Partners, L.P. (OTB), the Company owns and operates storage and terminaling assets located along the Gulf Coast of the United States on the Houston, Texas Ship Channel and in Beaumont, Texas. Its Houston and Beaumont terminals provides deep-water access and interconnectivity to refineries, chemical and petrochemical companies, carrier and pipelines and production facilities and have international distribution capabilities. Its facilities are directly connected to 18 refineries, storage facilities and production facilities along the Gulf Coast area through pipelines and common carrier pipelines, to end markets along the Gulf Coast and to the Cushing, Oklahoma storage interchange.
Houston Terminal
The Company operates third-party crude oil and refined petroleum products terminals on the Houston Ship Channel. Its facility has an aggregate active storage capacity of approximately 11.7 million barrels and provides integrated terminaling services to a variety of customers, including integrated oil companies, marketers, distributors and chemical companies. The principal products handled at its Houston terminal complex are crude oil, the inputs for chemical production (such as naphtha and condensate), which are referred to as chemical feedstocks, liquefied petroleum gas and clean petroleum products, such as gasoline and distillates, with crude oil accounting for approximately 64% of its active storage capacity.
The Company�� storage and distribution network is integrated with the Houston petrochemical and refining complex. The facility handles products through a number of transportation modes, primarily through pipelines interconnected to local refineries and production facilities, including Houston Refining�� refine! ry in Pasadena, Texas, PRSI�� refinery in Pasadena, Texas, ExxonMobil�� refinery in Baytown, Texas, which is a refinery in the United States. Its Houston terminal also handles products through third-party crude oil, refined petroleum products and liquified petroleum gas tankers and barges arriving at its deep-water docks. Its waterfront capabilities consists of six deep-water ship docks, allowing for the dockage of vessels with up to 130,000 deadweight tons (dwt), of cargo and vessel capacity, and two barge docks, allowing for barges with up to 20,000 dwt of cargo and barge capacity. Its deep-water ship docks can accommodate vessels with up to a 45 foot draft, including Suezmax tankers, which can navigate the Houston Ship Channel. During the year ended December 31, 2011 (during 2011), the Company generated 22% of its Houston terminal revenues from throughput fees charged to non-storage customers.
The Company�� real property at its Houston terminal consists of approximately 327 acres, including 63 acres of nearby parcels that could be connected to its Houston terminal through existing owned rights-of-way. The Company owns approximately 24 acres at the Crossroads Interchange approximately six miles from its Houston terminal.
Beaumont Terminal
The Company�� Beaumont terminal serves as a regional strategic and trading hub for vacuum gas oil and clean petroleum products for refineries located in the upper Gulf Coast region. Its facility has an aggregate active storage capacity of approximately 5.6 million barrels and provides integrated terminaling services to a variety of customers, including integrated oil companies, distributors, marketers and chemical and petrochemical companies. The principal products handled at its Beaumont terminal complex are refined petroleum products, which accounted for approximately 99% of its active storage capacity as of December 31, 2011.
The Company�� storage and distribution network is integrated with the Beaumon! t/Port Ar! thur petrochemical and refining complex, and provides its customers with the additional services of mixing, blending, heating and marine vapor recovery. Its Beaumont facility handles products through a number of transportation modes, primarily through third-party pipelines interconnected to local refineries and production facilities, through its own pipeline system to Huntsman�� chemical production facility in Port Neches, and through third-party crude and refined products tankers and barges arriving at its deep-water docks. Its waterfront capabilities consist of two deep-water ship docks, allowing for the dockage of vessels with up to 130,000 dwt of cargo and vessel capacity and drafts of up to 40 feet, and two barge docks, allowing for barges with up to 20,000 dwt of cargo and barge capacity and drafts of up to 12 feet.
Operations
The Company provides integrated terminaling, storage, pipeline and related services for third-party companies engaged in the production, distribution and marketing of crude oil, refined petroleum products and liquefied petroleum gas. The Company generates its revenues through the provision of fee-based services to its customers. During 2011, it generated approximately 75% of its revenues from fixed monthly fees for storage services, which its customers pay to reserve storage space in its tanks and to compensate the Company for receiving an agreed upon average periodic amount of product volume, or throughput, on their behalf.
Advisors' Opinion: - [By Richard Stavros]
The good news is that midstream MLPs are already part of the crude-by-rail story and will likely be part of the growing gas-by-rail story. Indeed, there are numerous names in the MLP space with at least some exposure to the crude-by-rail trend, including�Enterprise Products Partners LP�(NYSE: EPD), Kinder Morgan Energy Partners LP�(NYSE: KMP),�Genesis Energy LP�(NYSE: GEL), and�Oiltanking Partners LP�(NYSE: OILT),�among others. Barclays estimates that MLPs have already invested $2 billion in railroad terminals, including acquisitions.
- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Oiltanking Partners LP (NYSE: OILT) were down 7.23 percent to $59.79 after the company priced an offering of 2.6 million common units.
